Skip to content

Study · Not a test of the peptide alone · 1990

2 results

[A comparative evaluation of the efficacy of different therapeutic methods in sarcoidosis of the skin].

Samtsov AV

Vestnik dermatologii i venerologii1 Jan 1990

PMID2389612 (opens in a new tab)PepBankPUB-02389612
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In skin sarcoidosis patients, immunostimulating therapy involving thymalin and other immunoregulators failed.

    In plain wordsIn skin sarcoidosis patients, immunostimulating therapy involving thymalin and other immune treatments failed.

    Peptide
    Thymalin
    Outcome
    No significant changeTreatment response
    Study

    n = 28

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Immunostimulating therapy has failed.
    1 context sentence
    Summary · context
    Twenty-eight patients with skin sarcoidosis were treated with thymalin, thymogen, levamisole, dimocifon, with due consideration for their immune status.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with skin sarcoidosis, immunostimulating therapy including thymogen failed.

    In plain wordsIn patients with skin sarcoidosis, immunostimulating treatment including thymogen failed.

    Peptide
    Thymogen (oglufanide)
    Outcome
    No significant changeSkin sarcoidosis treatment response
    Study

    n = 28

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Immunostimulating therapy has failed.
    1 context sentence
    Summary · context
    Twenty-eight patients with skin sarcoidosis were treated with thymalin, thymogen, levamisole, dimocifon, with due consideration for their immune status.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.